Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Oct;39(14):2655-2663.
doi: 10.1038/s41433-025-03895-y. Epub 2025 Jul 19.

Visual acuity in various phenotypes of intermediate age related macular degeneration (AMD) in a multicentre cohort study in Europe- INTERCEPT-AMD report 1

Sarega Gurudas  1 , Inês Marques  2 , Jean-François Girmens  3 , Yara Lechanteur  4 , Maria Cristina Parravano  5 , Lieselotte Berger  6 , Hansjürgen Agostini  7 , Sandra Barrão  8 , Evangelos Tsiroukis  9 , Jordi Monés  10 , Laura Sararols  11 , Rufino Silva  12 , Hendrik Scholl  13 , Albrecht Lommatzsch  14 , Boris Stanzel  15 , Stela Vujosevic  16 , Sobha Sivaprasad  17 ; INTERCEPT-AMD Study Group
Collaborators, Affiliations
Multicenter Study

Visual acuity in various phenotypes of intermediate age related macular degeneration (AMD) in a multicentre cohort study in Europe- INTERCEPT-AMD report 1

Sarega Gurudas et al. Eye (Lond). 2025 Oct.

Abstract

Background/objectives: To study the associations of VA and intermediate age-related macular degeneration (iAMD) subclassifications.

Subjects/methods: This is the analysis of baseline data of a multicentre study on patients with iAMD in at least one eye. The subclassifications of iAMD were classified as: (i) iAMD with no evidence of incomplete retinal pigment epithelial and outer retinal atrophy (iRORA) or subretinal drusenoid deposits (SDD); (ii) iAMD with SDD with no iRORA; (iii) iAMD with iRORA with no SDD and (iv) iAMD with iRORA and SDD.

Results: 983 eyes from 805 patients with iAMD were analysed. The mean age was 75.8 years (SD 7.9), with 35.0% (282) male. Eyes with iRORA with SDD had lower VA relative to eyes with no iRORA and no SDD (OR = 0.98 [95% CI 0.96, 0.998]; P = 0.03). The VA in the better seeing eye was significantly higher than in the worse seeing eye. Increased age (sex adjusted OR, 1.07, 95% CI 1.05-1.09; P < 0.001) and female gender (age adjusted OR, 0.75, 95% CI 0.56-1.01; P = 0.057) were associated with SDD. Eyes with nAMD in the fellow eye had reduced odds of iRORA in the study eye (adjusted OR = 0.60, 95% CI 0.40-0.91; P = 0.015). Eyes with GA had increased odds of iRORA in the study eye (adjusted OR = 3.30, 95% CI 2.00-5.45; P < 0.001).

Conclusions: Baseline age, presence of SDD and/or iRORA and fellow eye status need to be considered in future clinical trials evaluating preventive or treatment options for iAMD.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. SS is the Editor-in-Chief of EYE.

Figures

Fig. 1
Fig. 1. Correlation of VA and age in different iAMD subgroups.
One eye with VA 20 excluded from the no atrophy & no SDD group. Beta coefficient for age obtained from linear mixed effects models, with random intercepts by participant which account for within participant correlation resulting from clustering of 2 eyes within the same participant. Participant subgroups presented in panels A no atrophy & no SDD, B no atrophy with SDD, C iRORA & no SDD, D iRORA with SDD. iRORA incomplete retinal pigment epithelium and outer retinal atrophy, SDD subretinal drusenoid deposits, VA visual acuity.
See this image and copyright information in PMC

References

    1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9:e144–e160. 10.1016/S2214-109X(20)30489-7. - DOI - PMC - PubMed
    1. Ferris FL 3rd, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51. - DOI - PMC - PubMed
    1. Vitale S, Agrón E, Clemons TE, Keenan TDL, Domalpally A, Danis RP, et al. Association of 2-year progression along the AREDS AMD scale and development of late age-related macular degeneration or loss of visual acuity: AREDS report 41. JAMA Ophthalmol. 2020;138:610–7. - DOI - PMC - PubMed
    1. Neelam K, Nolan J, Chakravarthy U, Beatty S. Psychophysical function in age-related maculopathy. Surv Ophthalmol. 2009;54:167–210. - DOI - PubMed
    1. Chandramohan A, Stinnett SS, Petrowski JT, Schuman SG, Toth CA, Cousins SW, et al. Visual function measures in early and intermediate age-related macular degeneration. Retin (Philos, Pa). 2016;36:1021–31. - DOI - PMC - PubMed

Publication types